BGI-Shenzhen and Complete Genomics Receive Clearance from China Regulatory Agency for Merger

BGI-Shenzhen ("BGI") and Complete Genomics

("Complete") announced Friday that they have obtained clearance from the National Development and Reform Commission of the People's Republic of China regarding BGI's proposed acquisition of Complete pursuant to the previously announced Agreement and Plan of Merger, dated as of September 15, 2012, among BGI, Beta Acquisition Corporation and Complete. BGI's financial advisor is Citi, and its legal counsel is O'Melveny & Myers LLP. Complete's financial adviser is Jefferies & Company, and its legal counsel is Latham & Watkins LLP. Stockholders with questions about the Offer or who need assistance with tendering their shares of common stock of Complete may call the Information Agent, Innisfree M&A Incorporated, toll-free, at (888) 750-5834. FORWARD-LOOKING STATEMENTS Certain statements either contained in or incorporated by reference into this document are forward-looking statements that involve risks and uncertainty. Future events regarding the proposed transactions and both the BGI's and Complete's actual results could differ materially from the forward-looking statements. Factors that might cause such a difference include, but are not limited to, statements regarding the combined companies' plans following, and the expected completion of, the proposed acquisition. These forward-looking statements involve